Status:
RECRUITING
Home Monitoring During Chemoradiation
Lead Sponsor:
University Medical Center Groningen
Collaborating Sponsors:
Siemens Corporation, Corporate Technology
Nova Biomedical
Conditions:
Locally Advanced Oesophageal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Chemoradiotherapy is part of standard treatment for patients with locally advanced oesophageal cancer. Some patients with oesophageal cancer treated with chemoradiotherapy do not complete treatment du...
Detailed Description
This is an observational feasibility study in which 30 ambulant patients with oesophageal cancer are continuously monitored from 1 week before chemoradiation until 3 weeks after chemoradiation for oes...
Eligibility Criteria
Inclusion
- Age ≥ 18 at the time of signing informed consent.
- Histologically proven adenocarcinoma, squamous cell carcinoma or mixed type of the oesophagus or gastro-oesophageal junction.
- Indication for definitive or neoadjuvant CRT, with chemotherapy that consists of weekly carboplatin/paclitaxel.
- Written, informed consent.
- Ability to comply with all protocol required actions (at home measurements are done individually by the participant him- or herself).
Exclusion
- \- Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent or the carrying out of the measurements at home.
Key Trial Info
Start Date :
May 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06597240
Start Date
May 15 2025
End Date
October 1 2026
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands, 9713 GZ